How will the market price of tazerestat change in 2025?

Tazemetostat is a targeted therapy drug mainly used to treat malignant tumors carrying EZH2 mutations. This drug is an EZH2 inhibitor that can inhibit the proliferation of cancer cells by blocking the expression of the EZH2 gene, thereby effectively slowing down the growth of tumors. Tazerestat is approved to treat certain types of cancer, including relapsed or refractory follicular lymphoma (FL; non-Hodgkin lymphoma) and epithelioid sarcoma (ES). Tazerestat provides a new treatment option for these cancers, which often leave patients with limited treatment options after failure of traditional treatments such as chemotherapy or radiation.

In terms of price, treatment with tazetostat is more expensive. In China, although tazetostat hydrobromide tablets (TAZVERIK/TAZVERIK) are already on the market, due to the short time the drug has been on the market in China and the unclear medical insurance reimbursement policy, it is usually difficult to purchase the drug through conventional channels. To meet demand, many patients have to purchase the drug through overseas channels.

In overseas markets, the original drug of tazetostat is relatively expensive. Taking the American version and the Japanese version as an example, the price of a medicine with a specification of 200mg*56 pills is about 10,000 to 20,000 yuan. Due to the high price, some patients may choose to purchase cheaper generic drugs to reduce the cost of treatment. Laotian generic drugs are a cheaper option, priced at more than 4,000 yuan, and their drug ingredients are basically the same as the original drugs.

Over time, it is expected that the price of tazetostat may be affected by health insurance policies and market competition in different countries. Over the longer term, drug prices may decline as more generics enter the market, but for most patients, drug cost remains an important factor in treatment decisions. Therefore, drug price fluctuations remain one of the key factors affecting patients' acceptance of treatment.

Reference materials:https://www.tazverik.com/